Top

Published in:

01-08-2016 | Oncology

Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment

Authors: Jan Baxa, Tana Matouskova, Gabriela Krakorova, Bernhard Schmidt, Thomas Flohr, Martin Sedlmair, Jiri Bejcek, Jiri Ferda

Published in: European Radiology | Issue 8/2016

Abstract

Objectives

To investigate the relationship of dual-phase dual-energy CT (DE-CT) and tumour size in the evaluation of the response to anti-EGFR therapy in patients with advanced non-small cell lung cancer (NSCLC).

Methods

Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). Iodine uptake (IU; mg/mL) was quantified using prototype software in arterial and venous phases; arterial enhancement fraction (AEF) was calculated. The change of IU before and after therapy onset was compared with anatomical evaluation in maximal transverse diameter and volume (responders vs. non-responders).

Results

A significant decrease of IU in venous phase was proved in responders according to all anatomical parameters (p=0.002–0.016). In groups of non-responders, a significant change of IU was not proved with variable trends of development. The most significant change was observed using the anatomical parameter of volume (cut-off 73 %). A significant difference of percentage change in AEF was proved between responding and non-responders (p=0.019–0.043).

Conclusion

Dual-phase DE-CT with iodine uptake quantification is a feasible method with potential benefit in advanced assessment of anti-EGFR therapy response. We demonstrated a decrease in vascularization in the responding primary tumours and non-significant variable development of vascularization in non-responding tumours.

Key Points

• Dual-phase DE-CT is feasible for vascularization assessment of NSCLC with anti-EGFR therapy.

• There was a significant decrease of iodine uptake in responding tumours.

• There was a non-significant and variable development in non-responding tumours.

• There was significant difference of AEF percentage change between responders and non-responders.

Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529CrossRefPubMed

Al-Farsi A, Ellis PM (2014) Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol 27:157

Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMed

Genestreti G, Grossi F, Genova C et al (2014) Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol 10:2081–2096CrossRefPubMed

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

Nishino M, Hatabu H, Johnson BE, McLoud TC (2014) State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology 271:6–27CrossRefPubMedPubMedCentral

Miles KA, Lee TY, Goh V et al (2012) Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 22:1430–1441CrossRefPubMed

Brix G, Griebel J, Kiessling F, Wenz F (2010) Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging 37:S30–S51CrossRefPubMed

Johnson TR, Krauss B, Sedlmair M et al (2007) Material differentiation by dual energy CT: initial experience. Eur Radiol 17:1510–1517CrossRefPubMed

10.

Zhang LJ, Zang GF, Wu SY, Xu J, Lu GM, Schoepf UJ (2013) Dual-energy CT imaging of thoracic malignancies. Cancer Imaging 13:81–91CrossRefPubMed

11.

Joo I, Lee JM, Kim KW, Klotz E, Han JK, Choi BI (2011) Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans: evaluation of the hemodynamic features and correlation with the chemotherapy response. Eur J Radiol 80:e278–e283CrossRefPubMed

12.

Tiseo M, Ippolito M, Scarlattei M et al (2014) Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemother Pharmacol 73:299–307CrossRefPubMed

13.

Tacelli N, Santangelo T, Scherpereel A et al (2013) Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol 23:2127–2136CrossRefPubMed

14.

van Elmpt W, Zegers CM, Das M, De Ruysscher D (2014) Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities. J Thorac Dis 6:319–327PubMedPubMedCentral

15.

Sauter AW, Winterstein S, Spira D et al (2012) Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med 53:521–529CrossRefPubMed

16.

van Elmpt W, Das M, Hüllner M et al (2013) Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiother Oncol 109:65–70CrossRefPubMedPubMedCentral

17.

Goh V, Ng QS, Miles K (2012) Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology? Invest Radiol 47:2–4CrossRefPubMed

18.

Shim SS, Lee KS, Kim BT et al (2005) Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236:1011–1019CrossRefPubMed

19.

Kim YN, Lee HY, Lee KS et al (2012) Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? Korean J Radiol 13:702–710CrossRefPubMedPubMedCentral

20.

Simons D, Kachelriess M, Schlemmer HP (2014) Recent developments of dual-energy CT in oncology. Eur Radiol 24:930–939CrossRefPubMed

21.

Toepker M, Moritz T, Krauss B et al (2012) Virtual non-contrast in second-generation, dual-energy computed tomography: reliability of attenuation values. Eur J Radiol 81:398–405CrossRef

22.

Uhrig M, Simons D, Ganten MK, Hassel JC, Schlemmer HP (2015) Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. Future Oncol 11:591–606CrossRefPubMed

23.

Knobloch G, Jost G, Huppertz A, Hamm B, Pietsch H (2014) Dual-energy computed tomography for the assessment of early treatment effects of regorafenib in a preclinical tumor model: comparison with dynamic contrast-enhanced CT and conventional contrast-enhanced single-energy CT. Eur Radiol 24:1896–1905CrossRefPubMed

24.

Baxa J, Vondráková A, Matoušková T et al (2014) Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response. Eur Radiol 24:1981–1988

25.

Tawfik AM, Razek AA, Kerl JM, Nour-Eldin NE, Bauer R, Vogl TJ (2014) Comparison of dual-energy CT-derived iodine content and iodine overlay of normal, inflammatory and metastatic squamous cell carcinoma cervical lymph nodes. Eur Radiol 24:574–580CrossRefPubMed

26.

Lind JS, Meijerink MR, Dingemans AM et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20:2890–2898CrossRefPubMedPubMedCentral

27.

Ng QS, Goh V, Fichte H et al (2006) Lung Cancer perfusion at multi-detector row CT:reproducibility of whole tumor quantitative measurements. Radiology 239:547–553CrossRefPubMed

28.

Kim KW, Lee JM, Klotz E et al (2009) Quantitative CT colour mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma. Radiology 250:425–434CrossRefPubMed

29.

Schmid-Bindert G, Henzler T, Chu TQ et al (2012) Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol 22:93–103CrossRefPubMed

30.

Werner-Wasik M, Xiao Y, Pequinot E, Curran WJ, Hauck W (2001) Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51:56–61CrossRefPubMed

Title: Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment
Authors: Jan Baxa
Tana Matouskova
Gabriela Krakorova
Bernhard Schmidt
Thomas Flohr
Martin Sedlmair
Jiri Bejcek
Jiri Ferda
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 8/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-4092-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 8/2016

Portrayal of radiology in a major medical television series: How does it influence the perception of radiology among patients and radiology professionals?

Erratum to: Short- and long-term effects of clinical audits on compliance with procedures in CT scanning

Navigated MRI-guided liver biopsies in a closed-bore scanner: experience in 52 patients

Non-contrast-enhanced MR angiography using time-spin labelling inversion pulse technique for detecting crossing renal vessels in children with symptomatic ureteropelvic junction obstruction: comparison with surgical findings

US-guided percutaneous treatment and physical therapy in rotator cuff calcific tendinopathy of the shoulder: outcome at 3 and 12 months

Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysis